$STTK News

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17

Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14

Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

What Shattuck Labs Stock Topped the Market on Monday

Raymond James Initiates Coverage On Shattuck Labs with Strong Buy Rating, Announces Price Target of $18

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $14

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs Q2 EPS $(0.12) Misses $(0.10) Estimate

JP Morgan Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $10

Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $16

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update - Slideshow

What's Going On With Shattuck Labs Stock Wednesday?

Shattuck Labs: "Hold" On Phase 1  SL-325 Data And Next Stage Of Development

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering